Enrich Therapeutics Inc. Secures Seed Funding from Connecticut Innovations and other Angel Investors

Groton, CT / Worcester, MA — July 15, 2020 Enrich therapeutics Inc. (founded in 2018), a device and application company focusing in unique single cell isolation technology, announced today that it successfully closed $320k in seed funding. The round was led by Connecticut Innovations, with participation from other angel investors in Boston Harbor Angels and Teich Technology Investments. This fund will support the ongoing development of Enrich’s proprietary single cell isolation platform.

Enrich Therapeutics develops NIAID funded novel single cell isolation platform to enhance global biomedical research at true single cell level with superior affordability and strength. Its static cell capture technology enables clone isolation under desired micro-environment with real-time monitoring. Enrich platform will have extensive impact in fields of basic biology, CAR-T, antibody, tumor genetics etc. Enrich team is committed to isolating single clones from any physiologically relevant scenario.

 

For more information:

E-mail: investors@enrichtx.com

Enrich Therapeutics Inc.

www.enrichtx.com